Video

Dr. Kumar Discusses Ixazomib in Multiple Myeloma

Author(s):

Shaji K. Kumar, MD

In Partnership With:

Shaji K. Kumar, MD, professor of Medicine, Mayo Clinic, discusses ixazomib (Ninlaro) in multiple myeloma.

Shaji K. Kumar, MD, professor of Medicine, Mayo Clinic, discusses ixazomib (Ninlaro) in multiple myeloma.

The proteasome inhibitor ixazomib is being evaluated in combination with lenalidomide (Revlimid) and dexamethasone in patients with newly diagnosed multiple myeloma.

Related Videos
4 experts are featured in this series.
Michael R. Bishop, MD
Lori A Leslie, MD
Andrew Ip, MD
Mansi R. Shah, MD
Elizabeth Buchbinder, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Alec Watson, MD
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, break down the current treatment landscape for relapsed/refractory follicular lymphoma.
Sagar D. Sardesai, MBBS
Related Content
Rafael Fonseca, MD
December 30th 2024

Working on the Frontlines of a Revolution in Multiple Myeloma Care

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

S. Vincent Rajkumar, MD
December 17th 2024

Research Shows New Treatment Could Delay Cancer Progression in Patients With High-Risk Smoldering Multiple Myeloma

Seth Wander, MD, PhD; Paolo Tarantino, MD; Daniel P. Petrylak, MD; Lionel A. Kankeu Fonkoua, MD; Solange Peters, MD, PhD; Edgardo Santos, MD, FACP, FCCP
October 9th 2023

Expert Insights on the United States Chemotherapy Shortage

Smoldering Myeloma
December 11th 2024

Cilta-Cel Leads to 100% MRD-Negativity Rate in High-Risk Smoldering Multiple Myeloma

Anitocabtagene Autoleucel in Multiple Myeloma | Image credit: © Nittaya – stock.adobe.com
December 11th 2024

Anitocabtagene Autoleucel Elicits Deep Responses in Relapsed/Refractory Multiple Myeloma